Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II

Maïlys Guillard, Eva Morava-Kozicz, Floris L. Van Delft, Rosie Hague, Christian Körner, Maciej Adamowicz, Ron A. Wevers, Dirk J. Lefeber

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BACKGROUND: Determination of the genetic defect in patients with a congenital disorder of glycosylation (CDG) is challenging because of the wide clinical presentation, the large number of gene products involved, and the occurrence of secondary causes of underglycosylation. Transferrin isoelectric focusing has been the method of choice for CDG screening; however, improved methods are required for the molecular diagnosis of patients with CDG type II. METHODS: Plasma samples with a typical transferrin isofocusing profile were analyzed. N-glycans were released from these samples by PNGase F [peptide-N4-(acetyl-β-glucosaminyl)-asparagine amidase] digestion, permethylated and purified, and measured on a MALDI linear ion trap mass spectrometer. A set of 38 glycans was used for quantitative comparison and to establish reference intervals for such glycan features as the number of antennae, the level of truncation, and fucosylation. Plasma N-glycans from control individuals, patients with known CDG type II defects, and patients with a secondary cause of underglycosylation were analyzed. RESULTS: CDGs due to mannosyl (α-1,6-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT2), β-1, 4-galactosyltransferase 1 (B4GALT1), and SLC35C1 (a GDP-fucose transporter) defects could be diagnosed directly from the N-glycan profile. CDGs due to defects in proteins involved in Golgi trafficking, such as subunit 7 of the conserved oligomeric Golgi complex (COG7) and subunit V0 a2 of the lysosomal H+-transporting ATPase (ATP6V0A2) caused a loss of triantennary N-glycans and an increase of truncated structures. Secondary causes with liver involvement were characterized by increased fucosylation, whereas the presence of plasma sialidase produced isolated undersialylation. CONCLUSIONS: MALDI ion trap analysis of plasma N-glycans documents features that discriminate between primary and secondary causes of underglycosylation and should be applied as the first step in the diagnostic track of all patients with an unsolved CDG type II.

Original languageEnglish (US)
Pages (from-to)593-602
Number of pages10
JournalClinical Chemistry
Volume57
Issue number4
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Glycosylation
Mass spectrometry
Polysaccharides
Mass Spectrometry
Plasmas
Congenital Disorders of Glycosylation
Defects
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Transferrin
amidase
Guanosine Diphosphate Fucose
Ions
Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase
Galactosyltransferases
Proton-Translocating ATPases
Asparagine
Neuraminidase
Isoelectric Focusing
Golgi Apparatus
Mass spectrometers

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Guillard, M., Morava-Kozicz, E., Van Delft, F. L., Hague, R., Körner, C., Adamowicz, M., ... Lefeber, D. J. (2011). Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. Clinical Chemistry, 57(4), 593-602. https://doi.org/10.1373/clinchem.2010.153635

Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. / Guillard, Maïlys; Morava-Kozicz, Eva; Van Delft, Floris L.; Hague, Rosie; Körner, Christian; Adamowicz, Maciej; Wevers, Ron A.; Lefeber, Dirk J.

In: Clinical Chemistry, Vol. 57, No. 4, 01.04.2011, p. 593-602.

Research output: Contribution to journalArticle

Guillard, M, Morava-Kozicz, E, Van Delft, FL, Hague, R, Körner, C, Adamowicz, M, Wevers, RA & Lefeber, DJ 2011, 'Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II', Clinical Chemistry, vol. 57, no. 4, pp. 593-602. https://doi.org/10.1373/clinchem.2010.153635
Guillard, Maïlys ; Morava-Kozicz, Eva ; Van Delft, Floris L. ; Hague, Rosie ; Körner, Christian ; Adamowicz, Maciej ; Wevers, Ron A. ; Lefeber, Dirk J. / Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. In: Clinical Chemistry. 2011 ; Vol. 57, No. 4. pp. 593-602.
@article{29d5da7e220d47338d90c8aacfcf9505,
title = "Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II",
abstract = "BACKGROUND: Determination of the genetic defect in patients with a congenital disorder of glycosylation (CDG) is challenging because of the wide clinical presentation, the large number of gene products involved, and the occurrence of secondary causes of underglycosylation. Transferrin isoelectric focusing has been the method of choice for CDG screening; however, improved methods are required for the molecular diagnosis of patients with CDG type II. METHODS: Plasma samples with a typical transferrin isofocusing profile were analyzed. N-glycans were released from these samples by PNGase F [peptide-N4-(acetyl-β-glucosaminyl)-asparagine amidase] digestion, permethylated and purified, and measured on a MALDI linear ion trap mass spectrometer. A set of 38 glycans was used for quantitative comparison and to establish reference intervals for such glycan features as the number of antennae, the level of truncation, and fucosylation. Plasma N-glycans from control individuals, patients with known CDG type II defects, and patients with a secondary cause of underglycosylation were analyzed. RESULTS: CDGs due to mannosyl (α-1,6-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT2), β-1, 4-galactosyltransferase 1 (B4GALT1), and SLC35C1 (a GDP-fucose transporter) defects could be diagnosed directly from the N-glycan profile. CDGs due to defects in proteins involved in Golgi trafficking, such as subunit 7 of the conserved oligomeric Golgi complex (COG7) and subunit V0 a2 of the lysosomal H+-transporting ATPase (ATP6V0A2) caused a loss of triantennary N-glycans and an increase of truncated structures. Secondary causes with liver involvement were characterized by increased fucosylation, whereas the presence of plasma sialidase produced isolated undersialylation. CONCLUSIONS: MALDI ion trap analysis of plasma N-glycans documents features that discriminate between primary and secondary causes of underglycosylation and should be applied as the first step in the diagnostic track of all patients with an unsolved CDG type II.",
author = "Ma{\"i}lys Guillard and Eva Morava-Kozicz and {Van Delft}, {Floris L.} and Rosie Hague and Christian K{\"o}rner and Maciej Adamowicz and Wevers, {Ron A.} and Lefeber, {Dirk J.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1373/clinchem.2010.153635",
language = "English (US)",
volume = "57",
pages = "593--602",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "4",

}

TY - JOUR

T1 - Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II

AU - Guillard, Maïlys

AU - Morava-Kozicz, Eva

AU - Van Delft, Floris L.

AU - Hague, Rosie

AU - Körner, Christian

AU - Adamowicz, Maciej

AU - Wevers, Ron A.

AU - Lefeber, Dirk J.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - BACKGROUND: Determination of the genetic defect in patients with a congenital disorder of glycosylation (CDG) is challenging because of the wide clinical presentation, the large number of gene products involved, and the occurrence of secondary causes of underglycosylation. Transferrin isoelectric focusing has been the method of choice for CDG screening; however, improved methods are required for the molecular diagnosis of patients with CDG type II. METHODS: Plasma samples with a typical transferrin isofocusing profile were analyzed. N-glycans were released from these samples by PNGase F [peptide-N4-(acetyl-β-glucosaminyl)-asparagine amidase] digestion, permethylated and purified, and measured on a MALDI linear ion trap mass spectrometer. A set of 38 glycans was used for quantitative comparison and to establish reference intervals for such glycan features as the number of antennae, the level of truncation, and fucosylation. Plasma N-glycans from control individuals, patients with known CDG type II defects, and patients with a secondary cause of underglycosylation were analyzed. RESULTS: CDGs due to mannosyl (α-1,6-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT2), β-1, 4-galactosyltransferase 1 (B4GALT1), and SLC35C1 (a GDP-fucose transporter) defects could be diagnosed directly from the N-glycan profile. CDGs due to defects in proteins involved in Golgi trafficking, such as subunit 7 of the conserved oligomeric Golgi complex (COG7) and subunit V0 a2 of the lysosomal H+-transporting ATPase (ATP6V0A2) caused a loss of triantennary N-glycans and an increase of truncated structures. Secondary causes with liver involvement were characterized by increased fucosylation, whereas the presence of plasma sialidase produced isolated undersialylation. CONCLUSIONS: MALDI ion trap analysis of plasma N-glycans documents features that discriminate between primary and secondary causes of underglycosylation and should be applied as the first step in the diagnostic track of all patients with an unsolved CDG type II.

AB - BACKGROUND: Determination of the genetic defect in patients with a congenital disorder of glycosylation (CDG) is challenging because of the wide clinical presentation, the large number of gene products involved, and the occurrence of secondary causes of underglycosylation. Transferrin isoelectric focusing has been the method of choice for CDG screening; however, improved methods are required for the molecular diagnosis of patients with CDG type II. METHODS: Plasma samples with a typical transferrin isofocusing profile were analyzed. N-glycans were released from these samples by PNGase F [peptide-N4-(acetyl-β-glucosaminyl)-asparagine amidase] digestion, permethylated and purified, and measured on a MALDI linear ion trap mass spectrometer. A set of 38 glycans was used for quantitative comparison and to establish reference intervals for such glycan features as the number of antennae, the level of truncation, and fucosylation. Plasma N-glycans from control individuals, patients with known CDG type II defects, and patients with a secondary cause of underglycosylation were analyzed. RESULTS: CDGs due to mannosyl (α-1,6-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT2), β-1, 4-galactosyltransferase 1 (B4GALT1), and SLC35C1 (a GDP-fucose transporter) defects could be diagnosed directly from the N-glycan profile. CDGs due to defects in proteins involved in Golgi trafficking, such as subunit 7 of the conserved oligomeric Golgi complex (COG7) and subunit V0 a2 of the lysosomal H+-transporting ATPase (ATP6V0A2) caused a loss of triantennary N-glycans and an increase of truncated structures. Secondary causes with liver involvement were characterized by increased fucosylation, whereas the presence of plasma sialidase produced isolated undersialylation. CONCLUSIONS: MALDI ion trap analysis of plasma N-glycans documents features that discriminate between primary and secondary causes of underglycosylation and should be applied as the first step in the diagnostic track of all patients with an unsolved CDG type II.

UR - http://www.scopus.com/inward/record.url?scp=79954626850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954626850&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2010.153635

DO - 10.1373/clinchem.2010.153635

M3 - Article

C2 - 21273509

AN - SCOPUS:79954626850

VL - 57

SP - 593

EP - 602

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 4

ER -